ACOR News and Press, Acorda Therapeutics Inc. From 02/17/20

Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Acorda Therapeutics, Inc. (ACOR) Q4 2019 Earnings Conference Call February 13, 2020 8:30 A.M. ET Company Participants Tierney Saccavino - Executive Vice President, Corporate Communications Ron Cohen - Chief Executive Officer Conference Call Participants Michael Yee - Jefferie...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...

Acorda Therapeutics (NASDAQ: ACOR ): Q4 Non-GAAP EPS of -$0.15 beats by $0.26 ; GAAP EPS of $1.38 beats by $2.33 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

2020 Guidance: Total net product revenue expected to be $120 - $150 million INBRIJA ® (levodopa inhalation powder) net revenue expected to be $35 - $40 million INBRIJA peak sales revised to $300 - $500 million AMPYRA ® (dalfampridine) Extended Release Tablets, ...

With another big day of news in the broader markets, some penny stocks have already begun to take off. The biggest focus right now is on momentum and what causes these moves in the first place. If you look at some of the pre-market news today, you can already see a bit of a trend forming. Earn...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA ® (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Mia...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2019 update and financial results on Thursday, February 13 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with this Read more ...

Acorda Therapeutics (NASDAQ: ACOR ) is down another 4.2% postmarket after holders filed to offer up to 9.599M shares of common stock. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...